fda compounding glp 1 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Navigating GLP-1 Compounding: FDA and
Description
Infant Drug Exposure via Breast Milk

Expert consensus on the application of oral hypoglycemic drugs in patients with cardiovascular disease complicated with diabetes mellitus

Endocrinology and Metabolism 308E414E425

Without sustained adherence, the wonder drug benefits of GLP-1s often cannot be fully realized
Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes

10.1111/jdi.12956 127 YingX.RongjiongZ.KahaerM.ChunhuiJ.WulasihanM
